Autolus Pivots Manufacturing Away from the US; TCR2 Takes Over Autolus’s Rockville Facility; Is Confidence in AUTO1 Wavering?
Here is a brief preview of this blast: On Monday, March 29, Autolus announced (press release) an update to their manufacturing strategy for the commercial supply of AUTO1 (CD19 CAR-T). Autolus aims to expand existing operations in the UK while terminating the lease for their US manufacturing facilities in Rockville, MD. Moreover, on the same day, TCR2 Therapeutics announced (press release) that they are seeking to accelerate commercial-scale manufacturing timelines by leasing a new manufacturing facility in Rockville, MD. Below, Celltelligence provides thoughts on Autolus’s manufacturing strategy, while contrasting Autolus’s possible headwinds with TCR2's potential opportunities.